PPD (NASDAQ:PPD) insider Karen Kaucic sold 20,574 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $34.80, for a total value of $715,975.20. Following the completion of the transaction, the insider now owns 8,392 shares of the company’s stock, valued at $292,041.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of PPD traded down $0.95 during mid-day trading on Thursday, reaching $36.04. 2,178,405 shares of the stock traded hands, compared to its average volume of 1,436,707. The firm has a market cap of $12.56 billion and a price-to-earnings ratio of 36.63. The stock has a fifty day simple moving average of $33.10 and a 200 day simple moving average of $27.14. PPD has a 12-month low of $10.61 and a 12-month high of $37.40.
PPD (NASDAQ:PPD) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $925.53 million. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 EPS. As a group, research analysts predict that PPD will post 0.18 earnings per share for the current year.
A number of analysts have issued reports on the company. Citigroup raised their price target on PPD from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Morgan Stanley increased their price objective on shares of PPD from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Mizuho increased their price objective on shares of PPD from $35.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Robert W. Baird increased their price objective on shares of PPD from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, September 21st. Finally, KeyCorp increased their price objective on shares of PPD from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, September 15th. Two investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. PPD currently has a consensus rating of “Buy” and a consensus price target of $33.93.
PPD Company Profile
PPD, Inc provides drug development services to the biopharmaceutical industry worldwide. The company offers clinical development and laboratory services to the pharmaceutical, biotechnology, and medical device and government organizations, as well as other industry participants. It operates in two segments, Clinical Development Services and Laboratory Services.
Featured Story: Depreciation
Receive News & Ratings for PPD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PPD and related companies with MarketBeat.com's FREE daily email newsletter.